Ameriprise’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.35M Sell
135,073
-7,188
-5% -$266K ﹤0.01% 2528
2025
Q4
$5.99M Sell
142,261
-9,420
-6% -$380K ﹤0.01% 2308
2025
Q3
$5.21M Buy
+151,681
New +$4.35M ﹤0.01% 2419
2025
Q2
Sell
-75,071
Closed -$2.23M 4137
2025
Q1
$2.23M Sell
75,071
-15,319
-17% -$584K ﹤0.01% 2837
2024
Q4
$3.58M Sell
90,390
-64
-0.1% -$2.42K ﹤0.01% 2595
2024
Q3
$3.08M Buy
+90,454
New +$2.54M ﹤0.01% 2692
2024
Q1
Sell
-22,179
Closed -$610K 3961
2023
Q4
$610K Sell
22,179
-146,910
-87% -$3.55M ﹤0.01% 3370
2023
Q3
$3.78M Sell
169,089
-5,010
-3% -$129K ﹤0.01% 2494
2023
Q2
$4.43M Buy
174,099
+49,558
+40% +$1.2M ﹤0.01% 2437
2023
Q1
$2.78M Buy
124,541
+3,963
+3% +$95.8K ﹤0.01% 2683
2022
Q4
$2.86M Sell
120,578
-14,131
-10% -$328K ﹤0.01% 2641
2022
Q3
$2.23M Sell
134,709
-35,919
-21% -$808K ﹤0.01% 2741
2022
Q2
$3.4M Sell
170,628
-5,204
-3% -$105K ﹤0.01% 2542
2022
Q1
$4.85M Sell
175,832
-24,098
-12% -$689K ﹤0.01% 2444
2021
Q4
$8.24M Buy
199,930
+162,535
+435% +$7.18M ﹤0.01% 2123
2021
Q3
$1.74M Sell
37,395
-10,041
-21% -$438K ﹤0.01% 2922
2021
Q2
$1.9M Buy
47,436
+42,784
+920% +$1.83M ﹤0.01% 2952
2021
Q1
$250K Buy
+4,652
New +$268K ﹤0.01% 3650
2020
Q3
Sell
-68,410
Closed -$1.77M 3791
2020
Q2
$1.77M Buy
68,410
+1,167
+2% +$29.1K ﹤0.01% 2671
2020
Q1
$1.64M Sell
67,243
-8,823
-12% -$222K ﹤0.01% 2576
2019
Q4
$2.12M Buy
76,066
+18,095
+31% +$468K ﹤0.01% 2707
2019
Q3
$1.39M Sell
57,971
-14,265
-20% -$379K ﹤0.01% 2866
2019
Q2
$2.06M Buy
+72,236
New +$1.8M ﹤0.01% 2744
2019
Q1
Sell
-94,980
Closed -$1.2M 3770
2018
Q4
$1.2M Buy
+94,980
New +$1.12M ﹤0.01% 2874
2014
Q4
Sell
-52,875
Closed -$516K 4395
2014
Q3
$516K Sell
52,875
-17,000
-24% -$223K ﹤0.01% 3037
2014
Q2
$1.2M Sell
69,875
-1,840
-3% -$26.5K ﹤0.01% 2710
2014
Q1
$1.23M Buy
71,715
+10,100
+16% +$161K ﹤0.01% 2652
2013
Q4
$893K Buy
+61,615
New +$802K ﹤0.01% 2694

Other funds holding VCYT

Ameriprise's VCYT Position: Q1 2026 in Review

Ameriprise reduced its Veracyte (VCYT) stake by 5.1% in Q1 2026, selling an estimated $266K and leaving 135,073 shares worth $4.35M. The position accounts for ﹤0.01% of the portfolio, ranked #2528.

Ameriprise first reported a position in VCYT in Q4 2013 and has held it in 28 quarters since. The position peaked at $8.24M in Q4 2021. 334 funds tracked by Wall St. Rank hold VCYT as of Q1 2026.

  • Ameriprise held 135,073 shares of Veracyte worth $4.35M as of Q1 2026.
  • Ameriprise sold 7,188 Veracyte shares in Q1 2026, an estimated $266K.
  • Veracyte made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #2528 holding.
  • Ameriprise first reported a position in Veracyte in Q4 2013 and has held it in 28 quarters since.
  • Ameriprise's Veracyte position peaked at $8.24M in Q4 2021.
  • 334 funds tracked by Wall St. Rank held Veracyte as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.